This study aims to evaluate how well the investigational drug NNC0487-0111, which contains the substance zenagamtide, works for people living with overweight or obesity and knee osteoarthritis. Knee osteoarthritis is a condition where the protective tissue that cushions the ends of the bones in the knee wears down over time, often leading to pain and stiffness. The study will compare the effects of different doses of this medication against a placebo.
Participants will receive the treatment through a subcutaneous injection, which means the medicine is administered into the fatty layer of tissue just under the skin, using a pre-filled pen once a week. Throughout the study, changes in body weight and levels of pain in the knee will be observed. Other factors such as physical function, waist size, and certain blood measurements like cholesterol and blood pressure may also be monitored to understand the overall impact of the treatment.



Bulgaria
Denmark
Greece
Italy
Poland
Spain